Recent Updates
Recently added Catalysts

Dasatinib as

Phase 1

Pharmacokinetic Study in Healthy Participants | Small molecule | Other |Bristol-Myers Squibb Company|Last Updated: Feb 11, 2013

Target and mechanism

ModalitySmall molecule

Also known as Dasatinib as tablets

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLED
Total Trials1
Total Enrollment141

FDA Designations

No designations recorded

Clinical trial landscape

Dasatinib as · 1 trial · 1 indication

Phase 1 1
NCT01392703Pharmacokinetic Study Comparing Blood Levels of Dasatinib in Healthy Participants Who Received the Tablet Formulation With Those Who Received Liquid and Tablet-dispersed FormulationsPharmacokinetic Study in Healthy Participants
COMPLETED141 Analytics
PHASE1COMPLETED
Pharmacokinetic Study Comparing Blood Levels of Dasatinib in Healthy Participants Who Received the Tablet Formulation With Those Who Received Liquid and Tablet-dispersed Formulations
Pharmacokinetic Study in Healthy ParticipantsUnlock trial analytics

Study Endpoints

Primary Endpoints

Maximum Observed Concentration (Cmax) of Dasatinib
Days 1-2, Days 5-6, and Days 9-10

Single-dose pharmacokinetic parameters, including Cmax, were derived using noncompartmental methods from plasma dasatinib concentration-time data.

Area Under the Plasma Concentration-time Curve From Zero to the Last Time of the Last Quantifiable Concentration (AUC[0-T])of Dasatinib
Days 1-2, Days 5-6, and Days 9-10

Single-dose pharmacokinetic, such as AUC(0-T),parameters were derived using noncompartmental methods from plasma dasatinib concentration-time data.

Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC[0-INF]) of Dasatinib
Days 1-2, Days 5-6, and Days 9-10

Single-dose pharmacokinetic parameters, such as AUC(0-INF) were derived using noncompartmental methods from plasma dasatinib concentration-time data.

Secondary Endpoints

Time of Maximum Observed Plasma Concentration (Tmax) of Dasatinib
Days 1-2, Days 5-6, and Days 9-10
Half-life of Dasatinib
Days 1-2, Days 5-6, and Days 9-10
Number of Participants With at Least 1 Adverse Event (AE), With at Least 1 Treatment-related AE, Who Discontinued Due to AEs, and With at Least 1 Serious Adverse Event (SAE)
Continually from enrollment through Day 9 and at study discharge on Day 10
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER

Treatment Arms

ArmTypeDescription
Dasatinib, 100 mg as tablets + waterOTHERTreatment A. Participants were randomized to and received treatment in 1 of 6 sequences (ABC, ACB, BCA, BAC, CAB, or CBA), administered over 3 1-day treatment periods (Days 1, 5, and 9), with treatment changing to next in the sequence at start of each new period. A 3-day washout period followed treatment periods 1 and 2.
Dasatinib, 100 mg as liquid + waterOTHERTreatment B. Participants were randomized to and received treatment in 1 of 6 sequences (ABC, ACB, BCA, BAC, CAB, or CBA), administered over 3 1-day treatment periods (Days 1, 5, and 9), with treatment changing to next in the sequence at start of each new period. A 3-day washout period followed treatment periods 1 and 2.
Dasatinib, 100 mg as tablets in orange juice + waterOTHERTreatment C. Participants were randomized to and received treatment in 1 of 6 sequences (ABC, ACB, BCA, BAC, CAB, or CBA), administered over 3 1-day treatment periods (Days 1, 5, and 9), with treatment changing to next in the sequence at start of each new period. A 3-day washout period followed treatment periods 1 and 2.

Interventions

NameTypeDescription
Dasatinib as tabletsDRUG2 50-mg tablets plus 240 mL noncarbonated, nonrefrigerated water. Oral, single dose, 1 day
Dasatinib as liquidDRUG100 mg administered as 10 mL of liquid drug (10 mg/mL) plus 230 mL noncarbonated, nonrefrigerated water. Oral, single dose, 1 day
Dasatinib as dispersed tabletsDRUG2 50-mg dispersed tablets in 30 mL of 100% orange juice followed by 15 mL of orange juice plus 195 mL noncarbonated, nonrefrigerated water. Liquid (oral solution), single dose, 1 day.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 55 Years
SexALL
Healthy VolunteersYes
Study Sites1

Key Inclusion Criteria: * Healthy participants, defined as having no clinically relevant deviation from normal in medical history, physical examination, electrocardiogram (ECG) findings, and clinical laboratory tests findings. * Body mass index of 18 to 32 kg/m\^2, inclusive * Age from 18 to 55 yea...

Countries:United States
Unlock Eligibility Criteria